Dosage of botulinum toxin in patients undergoing treatment for hemifacial spasm: is there modification during follow-up?

被引:0
作者
Dantas, Fatima de Menezes [1 ]
Freire, Felipe Olobardi [1 ]
Neto, Agabio Diogenes Pessoa [2 ]
Godeiro Junior, Clecio de Oliveira [3 ]
Alencar e Silva, Rodrigo [3 ]
机构
[1] Univ Fed Rio Grande do Norte, Ctr Ciencias Saude, Natal, RN, Brazil
[2] Inst Ensino & Pesquisa Alberto Santos Dumont, Ambulatorio Multiprofiss Doenca Parkinson, Macaiba, RN, Brazil
[3] Univ Fed Rio Grande do Norte, Hosp Univ Onofre Lopes, Serv Neurol, Natal, RN, Brazil
关键词
Hemifacial Spasm; Botulinum Toxins; Type A; LONG-TERM TREATMENT; CLINICAL-FEATURES; BLEPHAROSPASM; EFFICACY; SAFETY; PROGRESSION; INJECTIONS; DYSTONIA; DYSPORT; BOTOX;
D O I
10.1055/s-0044-1793935
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background The movement disorder known as hemifacial spasm is characterized by involuntary contractions of the muscles that are innervated by the facial nerve. The treatment of choice for this condition is botulinum toxin injections. Objective To analyze the botulinum toxin dosage in patients undergoing treatment for hemifacial spasm during a 14-year period. Methods A retrospective study of medical records from patients treated at the Neurology Service of Hospital Universit & aacute;rio Onofre Lopes, Universidade Federal do Rio Grande do Norte, from 2010 to 2024, was performed. Results A total of 151 patients met the inclusion criteria. The dose of botulinum toxin revealed a statistically significant increase during the first 3.46 years of follow-up. In the long-term, a trend toward dose stabilization was identified. The median latency for the onset of effect was 4 days, while the median duration of effect was 3 months. All side effects were temporary, with the most common being hemifacial weakness (17.9%) and palpebral ptosis (3.3%). Most patients presented primary hemifacial spasm (88.1%), with a neurovascular conflict identified in 24.1% of cases. Conclusion The increase in botulinum toxin dosage during the first years may be explained by dosage adjustment to control hemifacial spasm with the lowest possible doses. A prolonged interval between applications may also be associated with this increase. Dose stabilization tends to be achieved over time, indicating disease control.
引用
收藏
页码:13 / 13
页数:1
相关论文
共 39 条
[1]   Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm [J].
Ababneh, Osama H. ;
Cetinkaya, Altug ;
Kulwin, Dwight R. .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 (03) :254-261
[2]   How to face the hemifacial spasm: challenges and misconceptions [J].
Aktan, David ;
Depierreux, Frederique .
ACTA NEUROLOGICA BELGICA, 2024, 124 (01) :17-23
[3]  
[Anonymous], 2024, Botox (toxina botulinica A) Internet Sao Paulo Allergan Produtos Farmaceuticos Ltda
[4]  
[Anonymous], 2023, Dysport (toxina botulinica A) Internet Sao Paulo Beaufour Ipsen Farmaceutica Ltda
[5]   Botulinum toxin type A in the treatment of hemifacial spasm An 11-year experience [J].
Barbosa, Egberto Reis ;
Takada, Leonel Tadao ;
Goncalves, Lilian Regina ;
Paulo do Nascimento Costa, Rose Mary ;
Silveira-Moriyama, Laura ;
Chien, Hsin Fen .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2010, 68 (04) :502-505
[6]   Hemifacial spasm: clinical characteristics of 321 Indian patients [J].
Batla, Amit ;
Goyal, Chanchal ;
Shukla, Garima ;
Goyal, Vinay ;
Srivastava, Achal ;
Behari, Madhuri .
JOURNAL OF NEUROLOGY, 2012, 259 (08) :1561-1565
[7]   Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm [J].
Bentivoglio, A. R. ;
Fasano, A. ;
Ialongo, T. ;
Soleti, F. ;
Lo Fermo, S. ;
Albanese, A. .
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (03) :392-398
[8]  
Brazil. Ministry of Health. Health Care Secretariat, 2017, Ordinance n. 1. It approves the Clinical Protocol and Therapeutic Guidelines for Dystonias and Hemifacial Spasm
[9]  
Cardoso Junior J A., 2018, Faculdade de Medicina de Ribeirao Preto
[10]  
Chen Stephen R, 2018, Int Ophthalmol Clin, V58, P97, DOI 10.1097/IIO.0000000000000212